CN117084927A - Facial mask liquid composition, preparation method thereof and brightening facial mask - Google Patents
Facial mask liquid composition, preparation method thereof and brightening facial mask Download PDFInfo
- Publication number
- CN117084927A CN117084927A CN202311262315.9A CN202311262315A CN117084927A CN 117084927 A CN117084927 A CN 117084927A CN 202311262315 A CN202311262315 A CN 202311262315A CN 117084927 A CN117084927 A CN 117084927A
- Authority
- CN
- China
- Prior art keywords
- percent
- phase
- liquid composition
- skin
- mask liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 239000007788 liquid Substances 0.000 title claims abstract description 57
- 230000001815 facial effect Effects 0.000 title claims description 13
- 238000005282 brightening Methods 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 230000003750 conditioning effect Effects 0.000 claims abstract description 27
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 26
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 26
- 229960000367 inositol Drugs 0.000 claims abstract description 26
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 26
- -1 acyl anthranilic acid Chemical compound 0.000 claims abstract description 25
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 24
- 239000011570 nicotinamide Substances 0.000 claims abstract description 24
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 24
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 24
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 24
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 23
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 23
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 23
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims abstract description 23
- RWZYAGGXGHYGMB-UHFFFAOYSA-N o-aminobenzenecarboxylic acid Natural products NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000003906 humectant Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims description 29
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 230000001804 emulsifying effect Effects 0.000 claims description 14
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 13
- 229960000458 allantoin Drugs 0.000 claims description 13
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 229940101267 panthenol Drugs 0.000 claims description 8
- 235000020957 pantothenol Nutrition 0.000 claims description 8
- 239000011619 pantothenol Substances 0.000 claims description 8
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 34
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 57
- 230000000052 comparative effect Effects 0.000 description 24
- 230000007794 irritation Effects 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000002087 whitening effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
The invention discloses a mask liquid composition, a preparation method thereof and a brightening mask, wherein the mask liquid composition comprises a phase A and a phase B; based on the total weight of the mask liquid composition, the phase A comprises 0.2 to 0.4 percent of thickening agent, 7 to 16 percent of first humectant and the balance of solvent, and the phase B comprises 1.5 to 5 percent of first skin conditioning agent, 1 to 4 percent of second skin conditioning agent, 0.33 to 1.6 percent of third skin conditioning agent and 0.4 to 0.6 percent of second humectant; wherein the first skin conditioning agent comprises tranexamic acid and niacinamide, the second skin conditioning agent comprises hydroxyethylpiperazine ethane sulfonic acid and inositol, and the third skin conditioning agent comprises dihydrooat acyl anthranilic acid and dipotassium glycyrrhizinate. The mask liquid composition provided by the invention not only has the effect of quickly brightening, but also has the function of relieving, is mild and non-irritating, and is suitable for sensitive and fragile skin.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a mask liquid composition, a preparation method thereof and a brightening mask.
Background
The facial mask is an important category in the cosmetic skin care products, and has a large market proportion in the field of skin care products. The facial mask is prepared by using natural cotton or silk cloth as a carrier, soaking the natural cotton or silk cloth in facial mask liquid, and filling each bag with one piece of facial mask cloth. The product is convenient to use and carry, and can enable consumers to have a rest slightly after 15-30 minutes of face coating, and the effects of quickly supplementing water, repairing and brightening skin color can be easily achieved, so that the product is deeply favored by consumers.
At present, the types of facial masks on the market are various, and the effects of the facial masks are different. Although many masks have the effects of whitening and brightening, the effects can be exerted only after long-time use. Meanwhile, with the abuse of skin care products, the skin of a user is more sensitive, and the problems of redness, swelling, acne and the like are easy to occur. Therefore, it is necessary to provide a mask liquid with a soothing and quick lightening function.
Disclosure of Invention
The mask liquid composition provided by the invention not only has the effect of quickly brightening, but also has the function of relieving, is mild and non-irritating, and is suitable for sensitive and fragile skin.
In a first aspect, the present invention provides a mask liquid composition comprising a phase a and a phase B; the phase A comprises 0.2 to 0.4 percent of thickening agent, 7 to 16 percent of first humectant and the balance of solvent, and the phase B comprises 1.5 to 5 percent of first skin conditioner, 1 to 4 percent of second skin conditioner, 0.33 to 1.6 percent of third skin conditioner and 0.4 to 0.6 percent of second humectant according to the total weight of the mask liquid composition; wherein the first skin conditioning agent comprises tranexamic acid and niacinamide, the second skin conditioning agent comprises hydroxyethylpiperazine ethane sulfonic acid and inositol, and the third skin conditioning agent comprises dihydrooat acyl anthranilic acid and dipotassium glycyrrhizinate.
Tranexamic acid, also known as tranexamic acid, is used clinically mainly as an antifibrinolytic agent. It has been found that tranexamic acid can prevent ultraviolet-induced pigmentation, and because it is a plasmin inhibitor, it can reduce the accumulation of plasmin in melanocytes and interfere with the plasmin/zymogen system, thereby achieving the objective of reducing melanin production and transfer. In addition, tranexamic acid has the effects of reducing DNA damage, resisting oxidation and inflammation, promoting repair of skin barrier, inhibiting skin inflammation, and reducing wrinkles.
Nicotinamide is the amide form of niacin (vitamin B3). In cells, nicotinamide is used to synthesize Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Phosphate (NADP). Studies have shown that nicotinamide can down-regulate melanosome transport from melanocytes to keratinocytes without inhibiting tyrosinase activity or cell proliferation, thereby affecting skin pigmentation, and it can also interfere with cell signaling pathways between keratinocytes and melanocytes, reducing melanogenesis. On the other hand, nicotinamide acts on melanin already produced, reducing its transfer to superficial cells. When the nicotinamide is used as a whitening component, the concentration of the nicotinamide is 2% -5%, and the nicotinamide proves to have a certain effect on treating chloasma and hyperpigmentation caused by ultraviolet rays. Topical nicotinamide can increase the levels of free fatty acids and ceramides in the skin, stimulate microcirculation in the dermis and prevent loss of skin moisture. It also increases protein synthesis (e.g., keratin), increases intracellular NADPH levels, and accelerates differentiation of keratin cells. In addition, the irritation to the skin caused by the surfactant, the solvent and the like can be relieved. In addition, nicotinamide also has the effects of resisting aging, preserving moisture and the like. Hydroxyethyl piperazine ethane sulfonic acid is a very effective biological buffer, has strong water solubility, weak cell membrane permeability, strong acid-base continuity, almost no metal chelating property, strong chemical stability and no toxic effect on cells. The hydroxyethyl piperazine ethane sulfonic acid can reform the stratum corneum, promote metabolism of skin keratinocytes, and further promote metabolism of melanin; can soften cutin, promote the exfoliation of old cutin cells of skin epidermis, and reduce wrinkles.
Inositol, also known as inositol, is widely distributed in animals and plants, the most abundant stereoisomer of inositol among the celluloses and is the only biologically active considered as a growth factor for animals, microorganisms. Inositol can increase growth factors, keep the dermis layer stem cells prone to stability, and is beneficial to promoting the generation of fibroblast interstitial hyaluronic acid, collagen and elastin. Inositol can protect the keratinocytes from penetration and uv stress.
The dihydro oat acyl anthranilic acid can inhibit the activity of a receptor, reduce MC degranulation and inhibit keratinocytes and macrophages from releasing inflammatory factors such as IL-6 and the like; the anti-inflammatory, soothing and anaphylactic reaction relieving effects can be achieved by inhibiting the release of histamine by the mast cells and simultaneously preventing the P substance released by nerve endings from binding with NK-1 receptors of the mast cells.
Dipotassium glycyrrhizinate has various effects of inhibiting bacteria, diminishing inflammation, detoxifying, resisting allergy, deodorizing and the like, can prevent histamine from being released, effectively eliminates superoxide ions and hydroxyl radicals, remarkably inhibits the action of liposome peroxide, and is similar to the action of adrenocortical hormone; can neutralize or reduce toxic substances of cosmetics, and can also prevent allergic reaction of cosmetics.
In the invention, the inventor finds that the combined use of the skin conditioning agents of tranexamic acid, nicotinamide, hydroxyethyl piperazine ethane sulfonic acid, inositol, dihydro oat acyl anthranilic acid and dipotassium glycyrrhizinate produces a synergistic technical effect, so that the mask liquid composition has the effects of quickly brightening and relieving. Specifically, when tranexamic acid and nicotinamide are used in a matched mode, a cell passage can be opened, hydroxyethyl piperazine ethane sulfonic acid and inositol can quickly permeate into skin, and therefore an instant brightening effect is achieved.
In addition, when dipotassium glycyrrhizinate and dihydro oat acyl anthranilic acid are used together, fragile skin can be repaired, skin barrier is enhanced, mast cells are effectively protected, and release of inflammatory mediators is inhibited, so that the anti-inflammatory and soothing effects are good. Compared with the single use of dipotassium glycyrrhizinate, dihydro oat acyl anthranilic acid and other anti-inflammatory components, the dipotassium glycyrrhizinate and dihydro oat acyl anthranilic acid in the invention have the advantages that when combined use, the anti-inflammatory and soothing effects are obviously improved, and the use is safer, which indicates that the two anti-inflammatory components produce synergistic effect.
Further, the thickener comprises at least one of carbomer and hydroxyethyl cellulose; and/or the number of the groups of groups,
the first humectant comprises at least one of glycerin and butanediol; and/or, the second humectant comprises 1, 2-hexanediol; and/or the number of the groups of groups,
the solvent comprises water.
Further, the first skin conditioning agent comprises: 0.5 to 2 percent of tranexamic acid and 1 to 3 percent of nicotinamide; and/or, the second skin conditioning agent comprises: 0.5 to 2 percent of hydroxyethyl piperazine ethane sulfonic acid and 0.5 to 2 percent of inositol; and/or, the third skin conditioning agent comprises: 0.3 to 1.5 percent of dihydro oat acyl anthranilic acid and 0.03 to 0.1 percent of dipotassium glycyrrhizinate.
Further, the a phase further includes: 0.4 to 0.6 percent of antioxidant and 0.4 to 1 percent of fourth skin conditioner; the antioxidant comprises p-hydroxyacetophenone, and the fourth skin conditioner comprises at least one of panthenol and allantoin.
Panthenol, also known as vitamin B5, can be converted to pantothenic acid after long-term use and is synthesized into coa by tissues, which can be present in tissues and is essential for cellular material metabolism. The panthenol can improve cell activity, repair damaged skin and strengthen skin barrier function after long-term use. Allantoin has effects of promoting water absorption of skin and hair outermost layer tissue, reducing water loss, softening skin, improving elasticity, luster, preventing skin chapping, etc., and has unique property of keratolytic protein, and can promote cell metabolism, soften keratolytic protein, and reduce wrinkle. In addition, when allantoin is used in combination with dipotassium glycyrrhizinate and dihydro oat acyl anthranilic acid, the anti-inflammatory and soothing effects can be further improved.
Further, the B phase further includes: 0.05 to 0.1 percent of pH regulator and 1 to 3 percent of fifth skin conditioner; the pH adjuster comprises aminomethylpropanol and the fifth skin conditioner comprises a yeast extract.
In the invention, the yeast extract is rich in natural active ingredients such as small molecular amino acids, peptides, nucleotides, vitamins, mineral elements and the like, is easy to be absorbed and utilized by skin, can increase the immune function of the skin, and has the effects of moisturizing, repairing, supplementing nutrition for the skin and the like.
Further, based on the total weight of the mask liquid composition, the phase A consists of the following raw materials:
and (3) a thickening agent: 0.1 to 0.2 percent of carbomer and 0.1 to 0.2 percent of hydroxyethyl cellulose;
first humectant: 2-6% of glycerol and 5-10% of butanediol;
antioxidant: 0.4 to 0.6 percent of p-hydroxyacetophenone;
fourth skin conditioner: 0.3 to 0.8 percent of panthenol and 0.1 to 0.2 percent of allantoin;
solvent: the balance of water;
the phase B consists of the following raw materials in terms of the total weight of the mask liquid composition:
first skin conditioning agent: 0.5 to 2 percent of tranexamic acid and 1 to 3 percent of nicotinamide;
second skin conditioning agent: 0.5 to 2 percent of hydroxyethyl piperazine ethane sulfonic acid and 0.5 to 2 percent of inositol;
third skin conditioner: 0.3 to 1.5 percent of dihydro oat acyl anthranilic acid and 0.03 to 0.1 percent of dipotassium glycyrrhizinate;
fifth skin conditioner: 1-3% of yeast extract;
and a second humectant: 0.4 to 0.6 percent of 1, 2-hexanediol;
pH regulator: 0.05 to 0.1 percent of aminomethylpropanol.
Further, based on the total weight of the mask liquid composition, the phase A consists of the following raw materials:
and (3) a thickening agent: carbomer 0.15%, hydroxyethyl cellulose 0.12%;
first humectant: glycerol 4% and butanediol 6%;
antioxidant: 0.4% of p-hydroxyacetophenone;
fourth skin conditioner: 0.6% of panthenol and 0.2% of allantoin;
solvent: the balance of water;
the phase B consists of the following raw materials in terms of the total weight of the mask liquid composition:
first skin conditioning agent: 0.5% of tranexamic acid and 2% of nicotinamide;
second skin conditioning agent: 1% of hydroxyethyl piperazine ethane sulfonic acid and 1% of inositol;
third skin conditioner: 0.5% of dihydro oat acyl anthranilic acid and 0.05% of dipotassium glycyrrhizinate;
fifth skin conditioner: 2% of yeast extract;
and a second humectant: 0.4% of 1, 2-hexanediol;
pH regulator: aminomethylpropanol 0.09%.
In a second aspect, the present invention provides a method for preparing the foregoing mask liquid composition, including the following steps:
adding the phase A raw material into an emulsifying pot, heating to 80-85 ℃, and stirring at 600-800 rpm until the phase A raw material is completely dissolved; then continuing to homogenize for 3-5 min at the rotating speed of 1500-2000 rpm; after stopping homogenizing, preserving heat for 10-15 min and then cooling;
cooling the materials in the emulsifying pot to below 45 ℃, adding the B-phase raw material into the emulsifying pot, and stirring at 600-800 rpm until the B-phase raw material is completely dissolved; and then filtering and discharging to obtain the mask liquid composition.
Further, the preparation method of the mask liquid composition comprises the following steps:
adding the phase A raw material into an emulsifying pot, heating to 85 ℃, and stirring at 800rpm until the phase A raw material is completely dissolved; then, homogenizing for 5min at 1500 rpm; after stopping homogenizing, preserving heat for 15min, and cooling;
cooling the materials in the emulsifying pot to below 45 ℃, adding the B-phase raw material into the emulsifying pot, and stirring at 800rpm until the B-phase raw material is completely dissolved; and then filtering and discharging to obtain the mask liquid composition.
In a third aspect, the invention provides a lightening mask, comprising a mask substrate, wherein the mask substrate contains the mask liquid composition.
Through one or more of the above embodiments of the present invention, at least the following technical effects can be achieved:
1. in the mask liquid composition provided by the invention, when tranexamic acid and nicotinamide are matched for use, a cell passage can be opened, so that hydroxyethyl piperazine ethane sulfonic acid and inositol quickly permeate into skin, and an instant lightening effect can be achieved.
2. Compared with the single use of dipotassium glycyrrhizinate, dihydro oat acyl anthranilic acid and other anti-inflammatory components, the mask liquid composition provided by the invention has the advantages that when dipotassium glycyrrhizinate and dihydro oat acyl anthranilic acid are combined for use, a synergistic effect is generated, and the anti-inflammatory and soothing effects are obviously improved.
3. In the mask liquid composition provided by the invention, allantoin not only can promote metabolism of cells, soften keratin and reduce wrinkles, but also can play roles in moisturizing and repairing skin; in addition, when allantoin is used in combination with dipotassium glycyrrhizinate and dihydro oat acyl anthranilic acid, the anti-inflammatory and soothing effects can be further improved.
Drawings
FIG. 1 is a photograph of a mask fluid sample of example 1 and comparative example 1, respectively, applied to the arms of volunteers;
FIG. 2 is a diagram of the skin condition after 15 minutes of use;
where a is the sample using comparative example 1 and b is the sample using example 1.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings and the embodiments of the present invention. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to fall within the scope of the invention.
In the following examples and comparative examples, the raw materials used were all commercially available unless otherwise specified.
Examples 1 to 3
Examples 1-3 provide a mask liquid composition prepared from phase A and phase B raw materials, and the specific formula is shown in Table 1.
TABLE 1
The mask liquid composition can be prepared by the following steps:
s1, putting the raw materials 1-8 in the phase A into an emulsifying pot, heating to 85 ℃, stirring at a rotating speed of 800 until the raw materials in the phase A are completely dissolved and have no particles, and homogenizing at a rotating speed of 1500rpm for 5min; then keeping the temperature at 85 ℃ for 15min, and cooling for standby;
s2, cooling the materials in the emulsifying pot to below 45 ℃, adding 9-17 of B-phase raw materials, stirring at 800rpm for 10min to completely dissolve the B-phase raw materials without particles, filtering and discharging to obtain the mask liquid composition.
Comparative examples 1 to 5
Samples of the mask liquid compositions of comparative examples 1 to 5 were continuously prepared in the same manner as described above, wherein the formulations of comparative examples 1 to 5 are shown in Table 2:
TABLE 2
Efficacy testing
1. Whitening performance test
80 female volunteers aged 25-35 years were selected and divided into 8 groups of 10 persons each, and samples of examples 1-3 and comparative examples 1-5 of the present invention were applied, respectively. The using method comprises the following steps: the facial mask liquid composition sample is soaked by facial mask cloth and applied on an arm, and skin changes are observed after 15 minutes. Photographing before and after use. Scoring between 0 and 10 points according to the use effect: a score of 9-10 was good, 7-8 was good, 5-6 was general, 3-4 was poor, 1-2 was poor, and the average was taken and the results are shown in Table 3.
TABLE 3 Table 3
| Sample of | Scoring of |
| Example 1 | 9 |
| Example 2 | 9 |
| Example 3 | 8 |
| Comparative example 1 | 4 |
| Comparative example 2 | 4 |
| Comparative example 3 | 6 |
| Comparative example 4 | 6 |
| Comparative example 5 | 5 |
The results in table 1 show that the mask liquid compositions of examples 1-3 all have good whitening efficacy, with the whitening effect of examples 1 and 2 being optimal.
The mask liquid composition of comparative example 1 was added with hydroxyethylpiperazine ethanesulfonic acid and inositol, but not with tranexamic acid and nicotinamide, and the mask liquid composition of comparative example 2 was added with tranexamic acid and nicotinamide, but not with hydroxyethylpiperazine ethanesulfonic acid and inositol, and as a result, the whitening effect was significantly lower than that of the examples, and the whitening score was only 4. The reason for this is: although the hydroxyethyl piperazine ethane sulfonic acid, inositol, tranexamic acid and nicotinamide are all whitening components, the whitening effect is not obvious when the hydroxyethyl piperazine ethane sulfonic acid, inositol, tranexamic acid and nicotinamide are used alone, the whitening effect can be achieved only after long-term use, and the effect of rapid brightening is not achieved. When the components of the hydroxyethyl piperazine ethane sulfonic acid, the inositol, the tranexamic acid and the nicotinamide are used in a combined mode, the tranexamic acid and the nicotinamide can open a cell passage, and promote absorption of the hydroxyethyl piperazine ethane sulfonic acid and the inositol by cells, so that the hydroxyethyl piperazine ethane sulfonic acid and the inositol can quickly permeate into the skin, and an instant brightening effect can be achieved. Therefore, the mask liquid compositions of examples 1 to 3 are indispensable for hydroxyethyl piperazine ethane sulfonic acid, inositol, tranexamic acid and nicotinamide, and they are used in combination with each other to perform a synergistic effect. Fig. 1 and 2 are skin state diagrams before and after using the samples of example 1 and comparative example 1. As can be seen from fig. 2, the whiteness of the skin is obviously improved after the mask liquid composition of example 1 is applied for 15min, and the effect of instant lightening is achieved. Whereas the skin was substantially unchanged after 15 minutes of application using the mask liquid composition of comparative example 1.
2. Test of soothing efficacy
The mask liquid compositions of examples 1-3 and comparative examples 1-5 were diluted to 10mg/mL with 20mmol/L PBS solution and used as a sample solution to be measured. 90 female volunteers between 25 and 35 years of age were selected as subjects and randomized into 9 groups of 10 persons each. The sample solution of 0.1mL was sucked into the drug chamber of the plaque test tape (PBS solution was used as a blank control), and the plaque test tape with the sample solution was immediately attached to the arm of the volunteer while gently pressing the drug chamber one by one to expel air and uniformly distribute the sample. The test sites were marked for observation. The skin is applied once a day for 7 days. The product irritation is evaluated by adopting a scoring system, whether various irritation symptoms (including red swelling, erythema, tingling, itching, pimple and the like) appear or not is taken as an evaluation index, the score is 5 minutes full, the higher the score is, the smaller the skin irritation response is, and the average score is calculated after each group removes the highest score and the lowest score. The results are shown in Table 4.
TABLE 4 Table 4
| Sample of | Scoring of |
| Example 1 | 5.0 |
| Example 2 | 5.0 |
| Example 3 | 4.9 |
| Comparative example 1 | 4.7 |
| Comparative example 2 | 4.8 |
| Comparative example 3 | 3.9 |
| Comparative example 4 | 4.0 |
| Comparative example 5 | 3.7 |
| Blank control group | 5.0 |
As can be seen from table 4, the blank group used PBS solution, without any irritation to the skin. The mask liquid compositions of examples 1 to 3 also had very low irritation to the skin, and the irritation score reached 4.9 or more, wherein examples 1 to 2 were optimal, and the score reached 5.0, and were not irritating to the skin at all. Therefore, the mask liquid composition of the embodiment has excellent soothing performance and is mild and not irritating.
In the mask liquid composition of example 3, allantoin is not added in the formula, and the irritation score is 4.9, which indicates that the allantoin has a certain effect on the improvement of irritation, and when the allantoin is used together with the dihydro oat acyl anthranilic acid and the dipotassium glycyrrhizinate, the anti-inflammatory and soothing effects of the composition can be further improved.
In contrast, the mask liquid compositions of comparative examples 1 to 5 all had a certain irritation to the skin. Wherein, in comparative examples 3 to 4, when only one of the dihydrooat acyl anthranilic acid and dipotassium glycyrrhizinate was used, the skin still had relatively high irritation, and the irritation scores were only 3.9 and 4.0; however, the combination of dihydrooat acyl anthranilic acid and dipotassium glycyrrhizinate significantly improves irritation. This shows that the combination of the dihydro oat acyl anthranilic acid and the dipotassium glycyrrhizinate can produce a synergistic effect, thereby greatly enhancing the anti-inflammatory and soothing effects of the composition.
In conclusion, the mask liquid composition provided by the invention has the effects of quickly brightening and relieving, is mild and does not stimulate, and is suitable for sensitive and fragile skin through the use of the active ingredients of tranexamic acid, nicotinamide, hydroxyethyl piperazine ethane sulfonic acid, inositol, dihydro oat acyl anthranilic acid and dipotassium glycyrrhizinate.
In summary, although the present invention has been described in terms of the preferred embodiments, the preferred embodiments are not limited to the above embodiments, and various modifications and changes can be made by one skilled in the art without departing from the spirit and scope of the invention, and the scope of the invention is defined by the appended claims.
Claims (10)
1. A facial mask liquid composition is characterized by comprising a phase A and a phase B; the phase A comprises 0.2 to 0.4 percent of thickening agent, 7 to 16 percent of first humectant and the balance of solvent, and the phase B comprises 1.5 to 5 percent of first skin conditioner, 1 to 4 percent of second skin conditioner, 0.33 to 1.6 percent of third skin conditioner and 0.4 to 0.6 percent of second humectant according to the total weight of the mask liquid composition; wherein the first skin conditioning agent comprises tranexamic acid and niacinamide, the second skin conditioning agent comprises hydroxyethylpiperazine ethane sulfonic acid and inositol, and the third skin conditioning agent comprises dihydrooat acyl anthranilic acid and dipotassium glycyrrhizinate.
2. The mask liquid composition of claim 1, wherein the thickener comprises at least one of carbomer, hydroxyethyl cellulose; and/or the number of the groups of groups,
the first humectant comprises at least one of glycerin and butanediol; and/or, the second humectant comprises 1, 2-hexanediol; and/or the number of the groups of groups,
the solvent comprises water.
3. The mask liquid composition of claim 1 wherein the first skin conditioning agent comprises: 0.5 to 2 percent of tranexamic acid and 1 to 3 percent of nicotinamide; and/or, the second skin conditioning agent comprises: 0.5 to 2 percent of hydroxyethyl piperazine ethane sulfonic acid and 0.5 to 2 percent of inositol; and/or the number of the groups of groups,
the third skin conditioning agent comprises: 0.3 to 1.5 percent of dihydro oat acyl anthranilic acid and 0.03 to 0.1 percent of dipotassium glycyrrhizinate.
4. The mask liquid composition of claim 1, wherein the a phase further comprises: 0.4 to 0.6 percent of antioxidant and 0.4 to 1 percent of fourth skin conditioner; the antioxidant comprises p-hydroxyacetophenone, and the fourth skin conditioner comprises at least one of panthenol and allantoin.
5. The mask liquid composition of claim 1, wherein the B phase further comprises: 0.05 to 0.1 percent of pH regulator and 1 to 3 percent of fifth skin conditioner; the pH adjuster comprises aminomethylpropanol and the fifth skin conditioner comprises a yeast extract.
6. The mask liquid composition according to claim 4 or 5, wherein the a phase is composed of the following raw materials, based on the total weight of the mask liquid composition:
and (3) a thickening agent: 0.1 to 0.2 percent of carbomer and 0.1 to 0.2 percent of hydroxyethyl cellulose;
first humectant: 2-6% of glycerol and 5-10% of butanediol;
antioxidant: 0.4 to 0.6 percent of p-hydroxyacetophenone;
fourth skin conditioner: 0.3 to 0.8 percent of panthenol and 0.1 to 0.2 percent of allantoin;
solvent: the balance of water;
the phase B consists of the following raw materials in terms of the total weight of the mask liquid composition:
first skin conditioning agent: 0.5 to 2 percent of tranexamic acid and 1 to 3 percent of nicotinamide;
second skin conditioning agent: 0.5 to 2 percent of hydroxyethyl piperazine ethane sulfonic acid and 0.5 to 2 percent of inositol;
third skin conditioner: 0.3 to 1.5 percent of dihydro oat acyl anthranilic acid and 0.03 to 0.1 percent of dipotassium glycyrrhizinate;
fifth skin conditioner: 1-3% of yeast extract;
and a second humectant: 0.4 to 0.6 percent of 1, 2-hexanediol;
pH regulator: 0.05 to 0.1 percent of aminomethylpropanol.
7. The mask fluid composition of claim 6, wherein the phase a consists of the following materials, based on the total weight of the mask fluid composition:
and (3) a thickening agent: carbomer 0.15%, hydroxyethyl cellulose 0.12%;
first humectant: glycerol 4% and butanediol 6%;
antioxidant: 0.4% of p-hydroxyacetophenone;
fourth skin conditioner: 0.6% of panthenol and 0.2% of allantoin;
solvent: the balance of water;
the phase B consists of the following raw materials in terms of the total weight of the mask liquid composition:
first skin conditioning agent: 0.5% of tranexamic acid and 2% of nicotinamide;
second skin conditioning agent: 1% of hydroxyethyl piperazine ethane sulfonic acid and 1% of inositol;
third skin conditioner: 0.5% of dihydro oat acyl anthranilic acid and 0.05% of dipotassium glycyrrhizinate;
fifth skin conditioner: 2% of yeast extract;
and a second humectant: 0.4% of 1, 2-hexanediol;
pH regulator: aminomethylpropanol 0.09%.
8. A method of preparing the mask liquid composition according to any one of claims 1 to 7, comprising the steps of:
adding the phase A raw material into an emulsifying pot, heating to 80-85 ℃, and stirring at 600-800 rpm until the phase A raw material is completely dissolved; then continuing to homogenize for 3-5 min at the rotating speed of 1500-2000 rpm; after stopping homogenizing, preserving heat for 10-15 min and then cooling;
cooling the materials in the emulsifying pot to below 45 ℃, adding the B-phase raw material into the emulsifying pot, and stirring at 600-800 rpm until the B-phase raw material is completely dissolved; and then filtering and discharging to obtain the mask liquid composition.
9. The method of preparing a mask liquid composition according to claim 8, comprising the steps of:
adding the phase A raw material into an emulsifying pot, heating to 85 ℃, and stirring at 800rpm until the phase A raw material is completely dissolved; then, homogenizing for 5min at 1500 rpm; after stopping homogenizing, preserving heat for 15min, and cooling;
cooling the materials in the emulsifying pot to below 45 ℃, adding the B-phase raw material into the emulsifying pot, and stirring at 800rpm until the B-phase raw material is completely dissolved; and then filtering and discharging to obtain the mask liquid composition.
10. A lightening mask comprising a mask substrate, wherein the mask substrate comprises the mask liquid composition of any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311262315.9A CN117084927A (en) | 2023-09-27 | 2023-09-27 | Facial mask liquid composition, preparation method thereof and brightening facial mask |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311262315.9A CN117084927A (en) | 2023-09-27 | 2023-09-27 | Facial mask liquid composition, preparation method thereof and brightening facial mask |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117084927A true CN117084927A (en) | 2023-11-21 |
Family
ID=88783099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311262315.9A Pending CN117084927A (en) | 2023-09-27 | 2023-09-27 | Facial mask liquid composition, preparation method thereof and brightening facial mask |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117084927A (en) |
-
2023
- 2023-09-27 CN CN202311262315.9A patent/CN117084927A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110917051B (en) | Whitening essence and preparation method thereof | |
| CN104856892A (en) | Cosmetic or skin care product preparation rich in growth factors and preparation method therefor | |
| WO2005016364A1 (en) | Skin care composition including hexapeptide complexes and methods of their manufacture | |
| CN110123695B (en) | Cell energy restoration composition | |
| DE102009045798A1 (en) | Cosmetic agent, useful for lightening e.g. skin, comprises peroxidase and substrate for hydrogen peroxide producing enzyme in a first container, and hydrogen peroxide producing enzyme and substrate for the peroxidase in a second container | |
| CN110772444B (en) | Skin conditioner and mask for whitening and removing wrinkles and preparation method of skin conditioner and mask | |
| CN110623882A (en) | Whitening and freckle removing mask and preparation method thereof | |
| CN113304065B (en) | Scalp care composition and application thereof | |
| CN113576933A (en) | Composition with whitening effect and preparation method and application thereof | |
| CN110755348A (en) | Skin care composition and preparation method thereof | |
| CN110840782A (en) | Face-refreshing and skin-cleaning facial mask composition and preparation method thereof | |
| Preetha et al. | Cosmeceuticals–an evolution | |
| CN111514058A (en) | Skin whitening and brightening agent and preparation method thereof | |
| CN116509774B (en) | Anti-dandruff shampoo preparation containing sweet wormwood herb extract and preparation method thereof | |
| CN110693778A (en) | Face cream and production process thereof | |
| JPS63152309A (en) | External preparation of skin | |
| KR20060020630A (en) | Topical treatment of sebum related skin conditions | |
| US20180360712A1 (en) | Cosmetic composition and use thereof | |
| CN113648257A (en) | Whitening and freckle-removing composition and preparation method and application thereof | |
| KR102294232B1 (en) | Compositions and methods for reducing oxidative stress | |
| CN113332160A (en) | Cosmetic composition for conditioning peritrichotic skin | |
| JP3645318B2 (en) | Anti-aging skin external preparation | |
| CN115024991B (en) | Anti-aging composition and preparation method and application thereof | |
| CN117084927A (en) | Facial mask liquid composition, preparation method thereof and brightening facial mask | |
| RU2671511C1 (en) | Cosmetic composition for hair and head skin care (options) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |